Aurinia Presents New Data Highlighting Real-World Utilization and Value of LUPKYNIS in Treating Lupus Nephritis at American Society of Nephrology Kidney Week 2024 (Businesswire) - Oct 11, 2024 - "Aurinia Pharmaceuticals...announced today the acceptance of six abstracts, including five poster presentations, at the American Society of Nephrology (ASN) Kidney Week 2024 taking place in San Diego, CA October 23-27....New real-world baseline data from ENLIGHT-LN, a U.S.-based prospective, observational registry of adult patients with LN treated with LUPKYNIS: This initial analysis of baseline data from 123 patients with biopsy-confirmed LN who are initiating or have initiated treatment with LUPKYNIS within the last 12 months provides a critical foundation for understanding the real-world effectiveness and usage patterns of LUPKYNIS....Two new studies uncover the potential effects of LUPKYNIS on podocytes in LN and idiopathic nephrotic syndrome compared to older treatments."
Clinical data • Lupus Nephritis
|